Clinical epidemiology and treatment patterns of patients with multicentric Castleman disease: Results from two US treatment centres

Don Robinson, Matthew Reynolds, Corey Casper, Angela Dispenzieri, Jessica Vermeulen, Krista Payne, Judy Schramm, Kay Ristow, Marie Pierre Desrosiers, Karen Yeomans, Dana Teltsch, Richard Swain, Thomas Matthew Habermann, Philip Rotella, Helgi Van de Velde

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Multicentric Castleman disease (MCD) is a rare lymphoproliferative disease with little known about its epidemiology or treatment modalities. Clinical and demographic data of MCD patients identified between 2000 and 2009 were collected from medical records at two United States (US) MCD referral centres. ZIP codes identified patient residences; prevalence and incidence were estimated based on catchment areas. Patient clinical, demographic, and biochemical characteristics, drug therapies and medical utilization were descriptively reported. MCD patients (n = 59) were 61% male, mean age of 53 years (median = 55 years) and 68% Caucasian. Of those with known human immunodeficiency virus (HIV) status (n = 41), 85% (n = 35) were negative, 15% (n = 6) were positive. Most frequent physician-reported symptoms (n = 33) were fatigue (49%, n = 16), fever (39%, n = 13), and night sweats (30%, n = 10). The estimated US 10-year prevalence was 2·4 per million. During first year of follow-up after study entry, the top two systemic therapies (n = 27) were monotherapies: prednisone (33%, n = 9) and rituximab (19%, n = 5). After a follow-up of 2 years, 92% of patients were alive. This study provides new information on MCD population demographics, treatment patterns, and medical utilization; a minimal US period prevalence rate is proposed. Study replication is needed to improve external validity.

Original languageEnglish (US)
Pages (from-to)39-48
Number of pages10
JournalBritish Journal of Haematology
Volume165
Issue number1
DOIs
StatePublished - 2014

Fingerprint

Epidemiology
Demography
Therapeutics
Sweat
Rare Diseases
Prednisone
Medical Records
Fatigue
Fever
Referral and Consultation
Multi-centric Castleman's Disease
HIV
Physicians
Drug Therapy
Incidence
Population

Keywords

  • Castleman disease
  • Epidemiology
  • Healthcare utilization
  • Lymphoproliferative disorder
  • Treatment

ASJC Scopus subject areas

  • Hematology

Cite this

Clinical epidemiology and treatment patterns of patients with multicentric Castleman disease : Results from two US treatment centres. / Robinson, Don; Reynolds, Matthew; Casper, Corey; Dispenzieri, Angela; Vermeulen, Jessica; Payne, Krista; Schramm, Judy; Ristow, Kay; Desrosiers, Marie Pierre; Yeomans, Karen; Teltsch, Dana; Swain, Richard; Habermann, Thomas Matthew; Rotella, Philip; Van de Velde, Helgi.

In: British Journal of Haematology, Vol. 165, No. 1, 2014, p. 39-48.

Research output: Contribution to journalArticle

Robinson, D, Reynolds, M, Casper, C, Dispenzieri, A, Vermeulen, J, Payne, K, Schramm, J, Ristow, K, Desrosiers, MP, Yeomans, K, Teltsch, D, Swain, R, Habermann, TM, Rotella, P & Van de Velde, H 2014, 'Clinical epidemiology and treatment patterns of patients with multicentric Castleman disease: Results from two US treatment centres', British Journal of Haematology, vol. 165, no. 1, pp. 39-48. https://doi.org/10.1111/bjh.12717
Robinson, Don ; Reynolds, Matthew ; Casper, Corey ; Dispenzieri, Angela ; Vermeulen, Jessica ; Payne, Krista ; Schramm, Judy ; Ristow, Kay ; Desrosiers, Marie Pierre ; Yeomans, Karen ; Teltsch, Dana ; Swain, Richard ; Habermann, Thomas Matthew ; Rotella, Philip ; Van de Velde, Helgi. / Clinical epidemiology and treatment patterns of patients with multicentric Castleman disease : Results from two US treatment centres. In: British Journal of Haematology. 2014 ; Vol. 165, No. 1. pp. 39-48.
@article{0ae2ebcfa51447558d4d7c2f85e60af8,
title = "Clinical epidemiology and treatment patterns of patients with multicentric Castleman disease: Results from two US treatment centres",
abstract = "Multicentric Castleman disease (MCD) is a rare lymphoproliferative disease with little known about its epidemiology or treatment modalities. Clinical and demographic data of MCD patients identified between 2000 and 2009 were collected from medical records at two United States (US) MCD referral centres. ZIP codes identified patient residences; prevalence and incidence were estimated based on catchment areas. Patient clinical, demographic, and biochemical characteristics, drug therapies and medical utilization were descriptively reported. MCD patients (n = 59) were 61{\%} male, mean age of 53 years (median = 55 years) and 68{\%} Caucasian. Of those with known human immunodeficiency virus (HIV) status (n = 41), 85{\%} (n = 35) were negative, 15{\%} (n = 6) were positive. Most frequent physician-reported symptoms (n = 33) were fatigue (49{\%}, n = 16), fever (39{\%}, n = 13), and night sweats (30{\%}, n = 10). The estimated US 10-year prevalence was 2·4 per million. During first year of follow-up after study entry, the top two systemic therapies (n = 27) were monotherapies: prednisone (33{\%}, n = 9) and rituximab (19{\%}, n = 5). After a follow-up of 2 years, 92{\%} of patients were alive. This study provides new information on MCD population demographics, treatment patterns, and medical utilization; a minimal US period prevalence rate is proposed. Study replication is needed to improve external validity.",
keywords = "Castleman disease, Epidemiology, Healthcare utilization, Lymphoproliferative disorder, Treatment",
author = "Don Robinson and Matthew Reynolds and Corey Casper and Angela Dispenzieri and Jessica Vermeulen and Krista Payne and Judy Schramm and Kay Ristow and Desrosiers, {Marie Pierre} and Karen Yeomans and Dana Teltsch and Richard Swain and Habermann, {Thomas Matthew} and Philip Rotella and {Van de Velde}, Helgi",
year = "2014",
doi = "10.1111/bjh.12717",
language = "English (US)",
volume = "165",
pages = "39--48",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Clinical epidemiology and treatment patterns of patients with multicentric Castleman disease

T2 - Results from two US treatment centres

AU - Robinson, Don

AU - Reynolds, Matthew

AU - Casper, Corey

AU - Dispenzieri, Angela

AU - Vermeulen, Jessica

AU - Payne, Krista

AU - Schramm, Judy

AU - Ristow, Kay

AU - Desrosiers, Marie Pierre

AU - Yeomans, Karen

AU - Teltsch, Dana

AU - Swain, Richard

AU - Habermann, Thomas Matthew

AU - Rotella, Philip

AU - Van de Velde, Helgi

PY - 2014

Y1 - 2014

N2 - Multicentric Castleman disease (MCD) is a rare lymphoproliferative disease with little known about its epidemiology or treatment modalities. Clinical and demographic data of MCD patients identified between 2000 and 2009 were collected from medical records at two United States (US) MCD referral centres. ZIP codes identified patient residences; prevalence and incidence were estimated based on catchment areas. Patient clinical, demographic, and biochemical characteristics, drug therapies and medical utilization were descriptively reported. MCD patients (n = 59) were 61% male, mean age of 53 years (median = 55 years) and 68% Caucasian. Of those with known human immunodeficiency virus (HIV) status (n = 41), 85% (n = 35) were negative, 15% (n = 6) were positive. Most frequent physician-reported symptoms (n = 33) were fatigue (49%, n = 16), fever (39%, n = 13), and night sweats (30%, n = 10). The estimated US 10-year prevalence was 2·4 per million. During first year of follow-up after study entry, the top two systemic therapies (n = 27) were monotherapies: prednisone (33%, n = 9) and rituximab (19%, n = 5). After a follow-up of 2 years, 92% of patients were alive. This study provides new information on MCD population demographics, treatment patterns, and medical utilization; a minimal US period prevalence rate is proposed. Study replication is needed to improve external validity.

AB - Multicentric Castleman disease (MCD) is a rare lymphoproliferative disease with little known about its epidemiology or treatment modalities. Clinical and demographic data of MCD patients identified between 2000 and 2009 were collected from medical records at two United States (US) MCD referral centres. ZIP codes identified patient residences; prevalence and incidence were estimated based on catchment areas. Patient clinical, demographic, and biochemical characteristics, drug therapies and medical utilization were descriptively reported. MCD patients (n = 59) were 61% male, mean age of 53 years (median = 55 years) and 68% Caucasian. Of those with known human immunodeficiency virus (HIV) status (n = 41), 85% (n = 35) were negative, 15% (n = 6) were positive. Most frequent physician-reported symptoms (n = 33) were fatigue (49%, n = 16), fever (39%, n = 13), and night sweats (30%, n = 10). The estimated US 10-year prevalence was 2·4 per million. During first year of follow-up after study entry, the top two systemic therapies (n = 27) were monotherapies: prednisone (33%, n = 9) and rituximab (19%, n = 5). After a follow-up of 2 years, 92% of patients were alive. This study provides new information on MCD population demographics, treatment patterns, and medical utilization; a minimal US period prevalence rate is proposed. Study replication is needed to improve external validity.

KW - Castleman disease

KW - Epidemiology

KW - Healthcare utilization

KW - Lymphoproliferative disorder

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84896054346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896054346&partnerID=8YFLogxK

U2 - 10.1111/bjh.12717

DO - 10.1111/bjh.12717

M3 - Article

C2 - 24387011

AN - SCOPUS:84896054346

VL - 165

SP - 39

EP - 48

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -